Glaucoma is the second leading cause of irreversible vision loss in the world, responsible for approximately 15% of blindness worldwide, and it is estimated that 6.7 million of the 67 million people affected by Glaucoma worldwide are bilaterally blind (Quingley1996)^1.Glaucoma is not a single disease process but a group of disorders characterized by a progressive optic neuropathy resulting in a characteristic appearance of the optic disc and a specific pattern of irreversible visual field defects that are associated frequently but not invariably with raised intraocular pressure.²Several variants of Glaucoma exist, classified according to their etiology (i.e. congenital, primary or secondary), but the main types are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG).POAG is the most common type of Glaucoma.

Management of some of the ophthalmic condition is challenging to ophthalmologist till today, POAG is one among them.The current strategy of modern management of Glaucoma is mainly concentrated on lowering intra ocular pressure. A wide range of tropical & systemic anti- glaucoma medication is available in modern science such as-β-blockers, α-agonist, miotics, prostaglandin analogs etc. and the surgical procedures include-Trabeculotomy and other fistulizing anti-glaucoma surgeries. As the known medical as well as surgical procedures have their own limitations and side effects, no doubt these procedures bring down some of the symptoms but at the same time create one or the other problem.

Shigru pallava arka as in Tarpana & Aschyotana (eye drops) are being used by ophthalmic practitioners on Glaucoma patients and they report good results but scientific data is not reported. By virtue of its srotoshodhaka property it might be useful in relieving the symptoms of POAG. Safety profile of Shigru pallava arka will be done first before starting the Tarpana treatment on patients. Hence it is decided to evaluate the efficacy of Punarnavashtaka Kwath & Gokshuradi Guggulu orally and Shigru pallava arka locally. Before starting the treatment Kostha shodhana will be done for 3 days by erandbhristhaharitaki and Nasya with Anu taila for 7 days will be done.

GROUPING

The selected patients will be randomly divided into two groups: Group A (Trial group) and Group B (Control group).There will be 15 patients in each group.

CRITERIA FOR ASSESSMENT

Subjective Parameters:

• Blurred vision

• Delayed dark adaptation

          Objective Parameters:

·         Visual Acuity using snellens chart

·         Schiotz or Applanation Tonometry

·         Direct and indirect ophthalmoscopic examination

·         Fundus Photography

·         Automated perimetry (Base line, after 2 month)

·         OCT (if possible) to evaluate optic disc, optic cup.

Statistical test:       â€˜t’ test will be applied for calculating significance of the treatment.